Pacira BioSciences, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

25.20$ +0.8% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Pacira BioSciences, Inc. (PCRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 192 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement PCRX
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	68	73	69	71	67	79	75	84	83	95	91	103	105	122	106	76	117	131	119	136	128	159	158	169	167	172	160	169	164	181	167	178	169	187	169	181	180	197	177	192	746
Cost of Revenue	43	24	25	24	18	21	23	21	19	24	27	25	22	32	30	22	30	35	31	35	35	39	36	51	51	62	49	48	40	48	47	44	39	40	34	41	34	40	36	44	155
Gross Profit	25	49	45	47	49	58	52	63	64	71	64	77	82	91	76	53	87	96	88	100	93	120	122	119	117	110	111	121	124	134	120	134	130	147	135	140	145	157	141	148	591
Research & Development	9.8	17	17	19	12	10	14	12	15	14	14	18	20	20	16	14	15	15	16	13	12	16	22	26	19	18	17	19	21	19	18	20	19	24	25	28	26	37	28	30	122
Selling, General & Administrative	15	15	17	17	16	17	19	17	17	17	17	17	18	20	17	18	19	21	21	23	22	22	26	28	28	28	29	27	30	30	33	29	31	29	31	38	33	40	36	92	201
Total Operating Expenses	46	52	59	58	52	49	59	56	59	59	63	69	72	89	59	60	70	77	68	65	62	116	105	88	95	120	114	81	106	100	106	106	269	123	133	132	139	153	136	144	573
Operating Income	-21	-2.5	-14	-16	-3.6	8.5	-6.9	6.5	4.0	12	1.1	5.3	2.4	1.7	17	-7.1	18	19	19	35	31	4.2	17	31	21	-9.9	-3.1	40	18	33	13	28	-140	25	2.0	8.5	6.4	3.2	4.6	4.3	18
Interest Expense	1.6	1.9	2.6	5.2	5.1	5.1	5.2	5.4	5.6	5.8	5.8	5.9	5.9	6.0	6.0	5.5	7.1	7.1	7.0	7.0	7.3	10	10	8.8	9.9	11	9.6	3.9	3.5	3.4	3.3	3.1	4.7	3.8	4.6	4.7	3.7	3.4	3.2	3.6	14
Pre-Tax Income	-22	-4.0	-20	-20	-7.6	4.6	-11	2.6	-0.7	8.3	-2.5	1.1	-5.8	-3.5	8.6	-7.3	6.2	13	13	26	24	-6.2	7.3	22	2.1	-18	-26	38	17	34	14	37	-139	26	8.7	-1.9	9.5	0.6	5.0	2.6	18
Income Tax Expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	0.0	0.3	-1.6	0.3	1.3	0.4	0.0	-124	-1.8	2.4	6.6	6.6	-1.1	0.5	2.1	2.8	-8.0	-6.9	12	5.7	8.9	4.7	18	4.6	9.5	3.9	2.9	4.1	-1.1	2.1	-2.1	3.0
Net Income	-22	-4.0	-20	-20	-7.6	4.6	-11	2.6	-0.6	8.3	-2.8	2.7	-6.1	-4.9	8.2	-7.3	130	15	10	19	18	-5.1	6.8	20	-0.7	-10	-20	26	11	25	9.0	19	-143	16	4.8	-4.8	5.4	1.6	2.9	4.7	15
EBITDA	-17	1.1	-14	-11	0.9	13	-2.7	11	8.4	18	6.5	12	12	7.1	19	2.7	18	24	24	37	37	17	36	51	31	22	1.8	60	38	55	35	59	-115	51	34	29	34	25	30	26	115

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings